Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER 12 China: Oral semaglutide vs sitagliptin in type 2 diabetes on metformin
CTR20191201Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20191201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191201.